Strategies for chemokine antagonists as therapeutics

Seminars in Immunology

Volumn 15, Issue 1, 2003, Pages 57-65

  Proudfoot, Amanda E I ^a   Power, Christine A ^a   Rommel, Christian ^a   Wells, Timothy N C ^a  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

Author keywords

Chemokine; Chemokine receptor; Glycosaminoglycan; HIV; Inflammation; Receptor trafficking; Signaling

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; BB 100010; CD4 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CYTOKINE; GLYCOSAMINOGLYCAN; INTERLEUKIN 1; INTERLEUKIN 5; INTERLEUKIN 8; LIGAND; M T7 PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NEUTRALIZING ANTIBODY; RANTES; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL MODEL; ANTIVIRAL ACTIVITY; ASTHMA; ATHEROSCLEROSIS; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INFLAMMATION; KNOCKOUT MOUSE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL; RAT; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 0037300399     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-5323(02)00128-8     Document Type: Short Survey

References (64)

1. Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 1987;84:9233-7.
2. Rollins BJ, Stier P, Ernst T, Wong GG. The human homolog of the JE gene encodes a monocyte secretory protein. Mol Cell Biol 1989;9:4687-95.
3. Sherry B, Tekamp-Olson P, Gallegos C, Bauer D, Davatelis G, Wolpe SD, et al. Resolution of the two components of macrophage inflammatory protein 1 and cloning and characterization of one of those components, macrophage inflammatory proteins 1 beta. J Exp Med 1988;168:2251-9.
4. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-7.
5. Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a human interleukin-8 receptor. Science 1991;253:1278-80.
6. Murphy PM, Tiffany HL. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 1991;253:1280-3.
7. Neote K, DiGregorio D, Mak JY, Horuk R, Schall TJ. Molecular cloning, functional expression and signaling characteristics of a C-C chemokine receptor. Cell 1993;72:415-25.
8. Labriola-Tompkins E, Chandran C, Kaffka KL, Biondi D, Graves BJ, Hatada M, et al. Identification of the discontinuous binding site in human interleukin 1 beta for the type I interleukin 1 receptor. Proc Natl Acad Sci USA 1991;88:11182-6.
9. Schwartz TW, Rosenkilde MM. Is there a lock for all agonist keys in 7TM receptors? Trends Pharmacol Sci 1996;17:213-6.
10. Proudfoot AE. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002;2:106-15.
11. Power CA. Knock out models to dissect chemokine receptor function in vivo. J Immunol Methods, in press.
12. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka YK, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998;393:591-4.
13. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2(-/-) mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894-7.
14. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 2000;192:1075-80.
15. Chvatchko Y, Hoogewerf AJ, Meyer A, Alouani S, Juillard P, Buser R, et al. A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock. J Exp Med 2000;191:1755-63.
16. Humbles AA, Lu B, Friend DS, Okinaga S, Lora J, Al Garawi A, et al. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci USA 2002;99:1479-684.
17. Lukacs NW, Prosser DM, Wiekowski M, Lira SA, Cook DN. Requirement for the chemokine receptor CCR6 in allergic pulmonary inflammation. J Exp Med 2001;194:551-5.
18. Chensue SW, Lukacs NW, Yang TY, Shang X, Frait KA, Kunkel SL, et al. Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. J Exp Med 2001;193:573-84.
19. Marquez, G. Chemokines and asthma: evaluation of CCR8 as a potential therapeutic target. In: Proceedings of the Chemokine Conference, 2002; El Escorial, Spain.
20. Siciliano SJ, Rollins TE, DeMartino J, Konteatis Z, Malkowitz L, van Riper G, et al. Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci USA 1994;91:1214-8.
21. Clark-Lewis I, Schumacher C, Baggiolini M, Moser B. Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities. J Biol Chem 1991;266:23128-34.
22. Gong JH, Clark-Lewis I. Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues. J Exp Med 1995;181:631-40.
23. Zhang Y, Rollins BJ. A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. Mol Cell Biol 1995;15:4851-5.
24. Proudfoot AEI, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, et al. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996;271:2599-603.
25. Schwarz MK, Wells TN. New therapeutics that modulate chemokine networks. Nat Rev Drug Discov 2002;1:347-58.
26. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-703.
27. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000;97:5639-44.
28. Blanpain C, Buser R, Power CA, Edgerton M, Buchanan C, Mack M, et al. A chimeric MIP-1α/RANTES protein demonstrates the use of different regions of the RANTES protein to bind and activate its receptors. J Leukoc Biol 2001;69:977-85.
29. Cox MA, Jenh CH, Gonsiorek W, Fine J, Narula SK, Zavodny PJ, et al. Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol 2001;59:707-15.
30. Huang DR, Wang J, Kivisakk P, Rollins BJ, Ransohoff RM. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med 2001;193:713-26.
31. Liang M, Rosser M, Ng HP, May K, Bauman JG, Islam I, et al. Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor. Eur J Pharmacol 2000;389:41-9.
32. Liang M, Mallari C, Rosser M, Ng HP, May K, Monahan S, et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 2000;275:19000-8.
33. Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller SD. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995;155:5003-10.
34. Gonzalo JA, Lloyd CM, Albar JP, Wen D, Wells TNC, Proudfoot AEI, et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J Exp Med 1998;188:157-67.
35. Gonzalo JA, Pan Y, Lloyd CM, Jia GQ, Yu G, Dussault B, et al. Mouse monocyte-derived chemokine is involved in airway hyperreactivity and lung inflammation. J Immunol 1999;163:403-11.
36. Lloyd CM, Minto AW, Dorf ME, Proudfoot AEI, Wells TNC, Salant DJ, et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997;185:1371-80.
37. Horvath C, Welt FG, Nedelman M, Rao P, Rogers C. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ Res 2002;90:488-94.
38. Gong JH, Ratkay LG, Waterfield JD, Clark LI. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-1pr mouse model. J Exp Med 1997;186:131-7.
39. Plater-Zyberk C, Hoogewerf AJ, Proudfoot AEI, Power CA, Wells TNC. Effect of a CC chemokine receptor antagonist on collagen-induced arthritis in DBA/1 mice. Immunol Lett 1997;57:117-20.
40. Ajuebor MN, Hogaboam CM, Kunkel SL, Proudfoot AE, Wallace JL. The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J Immunol 2001;166:552-8.
41. Grone HJ, Weber C, Weber KC, Grone EF, Rabelink T, Klier CM, et al. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J 1999;13:1371-83.
42. Marshall E, Howell AH, Powles R, Hunter MG, Edwards M, Wood LM, et al. Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1α (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010. Eur J Cancer 1998;34:1023-9.
43. Clemons MJ, Marshall E, Durig J, Watanabe K, Howell A, Miles D, et al. A randomized phase-II study of BB-10010 (macrophage inflammatory protein-1 alpha) in patients with advanced breast cancer receiving 5-fluorouracil adriamycin, and cyclophosphamide chemotherapy. Blood 1998;92:1532-40.
44. Proudfoot AEI, Handel TM, Johnstone Z, Lau E, Liwang PJ, Clark-Lewis I, et al. Glycosaminoglycan binding and oligomerisation is essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA, submitted for publication.
45. Witt DP, Lander AD. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol 1994;4:394-400.
46. Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ, et al. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 1999;38:12959-68.
47. Lalani AS, Graham K, Mossman K, Rajarathnam K, Clark LI, Kelvin D, et al. The purified myxoma virus gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines. J Virol 1997;71:4356-63.
48. Liu L, Lalani A, Dai E, Seet B, Macauley C, Singh R, et al. The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury. J Clin Invest 2000;105:1613-21.
49. Curnock AP, Logan MK, Ward SG. Chemokine signaling: pivoting around multiple phosphoinositide 3-kinases. Immunology 2002;105:125-36.
50. Wymann MP, Sozzani S, Altruda F, Mantovani A, Hirsch E. Lipids on the move: phosphoinositide 3-kinases in leukocyte function. Immunol Today 2000;21:260-4.
51. Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L, et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000;287:1049-53.
52. Marignani PA, Carpenter CL. Vav2 is required for cell spreading. J Cell Biol 2001;154:177-86.
53. Chung CY, Lee S, Briscoe C, Ellsworth C, Firtel RA. Role of Rac in controlling the actin cytoskeleton and chemotaxis in motile cells. Proc Natl Acad Sci USA 2000;97:5225-30.
54. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV. Wu D. Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 2000;287:1046-9.
55. Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, Fernandez S, Martin DA, Jones DR, et al. Chemokine receptor homo- or heterodimerization activates distinct signaling pathways. EMBO J 2001;20:2497-507.
56. Wong M, Uddin S, Majchrzak B, Huynh T, Proudfoot AE, Platanias LC. et al. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. J Biol Chem 2001;276:11427-31.
57. Rodriguez-Frade JM, Mellado M, Martinez A. Chemokine receptor dimerization: two are better than one. Trends Immunol 2001;22:612-7.
58. Prado GN, Suzuki H, Wilkinson N, Cousins B, Navarro J. Role of the C terminus of the interleukin 8 receptor in signal transduction and internalization. J Biol Chem 1996;271:19186-90.
59. Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, Clapham PR, et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 1998;187:1215-24.
60. Zimmermann N, Conkright JJ, Rothenberg ME. CC chemokine receptor-3 undergoes prolonged ligand-induced internalization. J Biol Chem 1999;274:12611-8.
61. Elsner J, Dulkys Y, Kimmig D, Wells TN, Proudfoot AE, Kapp A. Aminooxypentane-RANTES induces CCR3 activation and internalization of CCR3 from the surface of human eosinophils. Int Arch Allergy Immunol 2001;124:227-9.
62. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103:807-15.
63. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-9.
64. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by the cytokine RANTES. Nature 1990;347:669-71.